| NCT#: & Link | NCT03785249 |
| NCT QR Code |  |
| Available as of: | July 15 2024 |
| Contract: | Caris |
| Indication Category: | Solid Tumors |
| Study Sponsor: | Mirati Therapeutics |
| Protocol #: | 849-001 |
| Title: | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 |
| Highlight Details: | ***REFERRAL ONLY*** A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation |
| Biomarkers: | KRAS G12C |
| Indication: | PDAC, Other Solid Tumors |
| Phase: | 1/2 |
| Treatment Line: | |
| Study Drug/Test Compound: | Adagrasib (MRTX849) |
| Notes | |
| Recruitment Status: | Just In Time |
| Participating Institution: | Salinas Valley Health |
| Salinas Valley Health Clinical Research Program: | Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected] |
(Tumor Board) & Other Clinical Trials at Salinas Valley Health
